Dr. Schneider’s lab focuses on HIV antibody distribution. He has helped develop a platform to track intravenous injected fluorophore conjugated IgG in plasma, tissue, and weck-cel fluid. This methodology has led to a grant to study how the timing of antibody injection affects distal site accumulation of virus following challenge. Through a better understanding of how antibodies get to and fortify mucosal surfaces from incoming pathogens, this research has the potential to elucidate novel HIV prevention strategies with the ultimate goal of blocking initial HIV transmission. This work will help inform future passive immunization studies, such as the AMP (Antibody Mediated Prevention) trial which is currently underway and administering anti-HIV antibodies to at-risk individuals around the world. As the SARS-CoV-2 pandemic emerged, I have adapted my work with HIV antibodies to better understand the neutralizing antibody response in COVID-19 patients.

My Scopus ID is 55465896500.

Research Areas:
HIV pathogenesis, broadly neutralizing antibodies, passive immunization, and COVID-19.

My Faculty Profile at Rush University Medical Center:
https://www.rushu.rush.edu/faculty/jeffrey-schneider-phd

My Laboratory:
https://www.rushu.rush.edu/research/departmental-research/microbial-pathogens-and-immunity-research/laboratory-jeffrey-schneider-phd

My NCBI Bibliography:
https://www.ncbi.nlm.nih.gov/myncbi/jeffrey.schneider.2/bibliography/public/

My Scopus:
https://www.scopus.com/authid/detail.uri?authorId=55465896500

Education:
PhD, Molecular Pathogenesis and Molecular Medicine, University of Chicago
BS, Bioengineering, University of Illinois Urbana-Champaign